Who is Amy W. Schulman and why is her appointment significant?

Amy W. Schulman is a newly elected independent director to Elevance Health's Board. Her appointment is significant due to her immediate assignment to the Audit and Finance Committees, indicating her strong financial expertise and the company's confidence in her oversight capabilities.

What are the implications of Ms. Schulman being an "audit committee financial expert"?

Ms. Schulman's qualification as an "audit committee financial expert" means she possesses a deep understanding of accounting principles and financial reporting, which is crucial for the Audit Committee's responsibilities in overseeing financial statements, internal controls, and the audit process. This enhances the board's financial governance.

How will Ms. Schulman be compensated for her role?

Ms. Schulman will be compensated in accordance with Elevance Health's standard compensation program for its non-employee directors. Details of this program are available in Exhibit 10.7 of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Does Ms. Schulman have any conflicts of interest or special arrangements for her election?

The filing explicitly states there are no arrangements or understandings between Ms. Schulman and any other person regarding her election. She also has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K, confirming her independence.

ELV 8-K: Leadership Changes

Summary

Elevance Health, Inc. (ELV) has announced a significant addition to its Board of Directors through an 8-K filing on December 10, 2025. The company elected Amy W. Schulman as an independent director, effective January 12, 2026, with her term extending to the 2028 annual meeting of shareholders. This appointment is notable as Ms. Schulman brings expertise that has also led to her appointment on the Audit and Finance Committees, positions critical for financial oversight. Investors should note that Ms. Schulman has been deemed an independent director by both NYSE listing standards and the company's own guidelines. Furthermore, she meets the criteria for an "audit committee financial expert" according to SEC regulations, underscoring her qualifications for these key financial governance roles. Her compensation will follow the company's standard non-employee director program. The company also furnished a press release detailing this election as an exhibit.

Key Highlights

1Amy W. Schulman elected as an independent director to the Board, effective January 12, 2026.
2Ms. Schulman's term as director will expire at the 2028 annual meeting of shareholders.
3Appointed to serve on both the Audit and Finance Committees of the Board.
4Determined to be an independent director under NYSE listing standards and company guidelines.
5Qualified as an "audit committee financial expert" per SEC regulations.
6Ms. Schulman's election was announced via a press release filed as an exhibit.
7Compensation for Ms. Schulman will be in line with the standard program for non-employee directors.

Elevance Health, Inc. 8-K Report, Executive Changes (Dec 10, 2025)

Summary

Key Highlights

Frequently Asked Questions